CORTI, CHIARA
CORTI, CHIARA
Dipartimento di Oncologia ed Emato-Oncologia
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2025 P.P.M. Berton Giachetti, S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M.G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, G. Bianchini, G. Curigliano, C. De Angelis, C. Criscitiello
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy
2025 C. Corti, B. Binboğa Kurt, B. Koca, T. Rahman, F. Conforti, L. Pala, G. Bianchini, C. Criscitiello, G. Curigliano, A.C. Garrido-Castro, S.K. Kabraji, A.G. Waks, E.A. Mittendorf, S.M. Tolaney
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow
2024 M. Cobanaj, C. Corti, E.C. Dee, L. Mccullum, L. Boldrini, I. Schlam, S.M. Tolaney, L.A. Celi, G. Curigliano, C. Criscitiello
Cardiotoxicity of Agents Used in Patients With Breast Cancer
2024 P. Zagami, D. Trapani, E. Nicolò, C. Corti, C. Valenza, C. Criscitiello, G. Curigliano, L.A. Carey
Second Malignancy Probabilities in Patients With Breast Cancer Treated With Conventional Versus Hypofractionated External Beam Radiation Therapy in the Adjuvant Setting
2024 T.A. Patel, B. Jain, H.L. Cho, C. Corti, N. Vapiwala, F. Chino, J.E. Leeman, E.C. Dee
Can we ensure a safe and effective integration of language models in oncology?
2024 C. Corti, L.A. Celi
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials
2023 G. Castellano, C. Corti, L. Boldrini, L. Gervaso, C. Criscitiello, G. Curigliano
HER2-Low Breast Cancer: a New Subtype?
2023 C. Corti, F. Giugliano, E. Nicolò, P. Tarantino, C. Criscitiello, G. Curigliano
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
2023 S. Morganti, S. Gandini, E. Nicolo, E. Zattarin, C. Corti, A. Verrazzo, P.P.M.B. Giachetti, C. Sposetti, M.G. Razeti, B.T. Salimbeni, L. Boldrini, A.C. Schianca, R. Caputo, C. Vernieri, E. Munzone, M. Lambertini, M. De Laurentiis, G. Viale, G. Curigliano, C. Criscitiello
Broadening the scope of artificial intelligence in oncology
2023 R. Ravella, E.C. Dee, C. Corti, L.A. Celi, P. Iyengar
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
2023 C. Corti, C. De Angelis, G. Bianchini, L. Malorni, M. Giuliano, E. Hamilton, R. Jeselsohn, K. Jhaveri, G. Curigliano, C. Criscitiello
Exploring the utility and limitations of ChatGPT in scientific literature searches
2023 C. Corti, G. Castellano, G. Curigliano
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care
2023 C. Corti, M. Cobanaj, E.C. Dee, C. Criscitiello, S.M. Tolaney, L.A. Celi, G. Curigliano
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
2023 G. Antonarelli, C. Corti, P. Tarantino, B.T. Salimbeni, P. Zagami, A. Marra, D. Trapani, S. Tolaney, J. Cortes, G. Curigliano
High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study
2023 F. Conforti, L. Pala, G. Vivanet, C. Corti, C. Catania, D. Maiettini, G. Varano, B. Di Venosa, G. Curigliano, P. Salvini, R. Berardi, Z. Ballatore, T.M. De Pas
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread
2023 C. Criscitiello, C. Corti, M. De Laurentiis, G. Bianchini, B. Pistilli, S. Cinieri, L. Castellan, G. Arpino, P. Conte, F. DI MECO, A. Gennari, V. Guarneri, L. Visani, L. Livi, P. Marchetti, F. Puglisi, G. Viale, L. Del Mastro, S. De Placido, G. Curigliano
Artificial intelligence as an adjunct tool for breast oncologists – are we there yet?
2023 S.I. I., M. Saad Menezes, C. Corti, A. Tan, I. Abuali, S. Tolaney
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives
2023 C. Valenza, G. Rizzo, M.I. Passalacqua, L. Boldrini, C. Corti, D. Trapani, G. Curigliano
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023 E. Zattarin, D. Presti, L. Mariani, C. Sposetti, R. Leporati, A. Menichetti, C. Corti, C. Benvenuti, G. Fucà, R. Lobefaro, F. Ligorio, L. Provenzano, A. Vingiani, M. Del Vecchio, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, A. Esposito, C.A. Giorgi, L. Lalli, L. Boldrini, P.P.B. Giacchetti, A.C. Schianca, V. Guarneri, R. Pedersini, A. Losurdo, A. Zambelli, D. Generali, C. Criscitiello, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri